Targeting Inflammation In Atherosclerosis After Darapladib: Does The IL-6 Pathway Hold The Answer?
This article was originally published in Pharmaceutical Approvals Monthly
Targeting inflammation appears to be a promising complementary approach to lipid-lowering drugs in atherosclerosis, but the question of which pathway in a complex system to target remains open. The failure of GlaxoSmithKline’s darapladib in the STABILITY trial may have dealt a fatal blow to phospholipase A2 enzymes as targets, but the interleukin-6 pathway is gaining attention with the ongoing CANTOS study of Novartis’ canakinumab and the NHLBI’s CIRT study of low-dose methotrexate.
You may also be interested in...
GlaxoSmithKline’s decision to end a Phase III trial testing the cancer immunotherapy MAGE-A3 in NSCLC is no surprise, following disappointing results in two trials, but coupled with other disappointing R&D news it puts more pressure on the company to deliver on its respiratory launches.
Company announces that Lp-PLA2 inhibitor darapladib fails Phase III STABILIITY outcomes study, the latest in a string of pharma CV failures.
Decreasing cardiovascular events is the only endpoint that matters for cholesterol-lowering drugs, FDA official says at Amarin’s negative Vascepa panel, leaving little room for drug’s expanded approval based on a surrogate endpoint.